Resmed Inc. · NYSE:RMD
Resmed — Investor Presentation (September 2025)
18 slides from Resmed's investor presentation, September 2025
Slide 1: Resmed Corporate Overview
Resmed Corporate Overview September 2025 June 4, 2025
Slide 2: Presentation of Financial Information & Forward-Looking Statements
Presentation of Financial Information & Forward-Looking Statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities for the periods indicated. This presentation includes financial information prepar
Slide 3: Resmed – A Global Leader in Connected and Digital Solutions for Sleep and Breathing Health
Resmed – A Global Leader in Connected and Digital Solutions for Sleep and Breathing Health Our Businesses Sleep and Breathing Health (SBH) Residential Care Software (RCS) • Devices and masks designed to treat and manage • Out-of-Hospital software products sleep apnea, COPD and other sleep and breath
Slide 4: Resmed Has a Strong Track Record of Industry Leadership, Financial Performance and Value Creation
Resmed Has a Strong Track Record of Industry Leadership, Financial Performance and Value Creation Founded FY25 Results 1989 Revenue Free Cash Flow1 $5.1B 12% $1.7B 19% 5-YEAR 5-YEAR CAGR CAGR Impact GAAP Operating Income Non-GAAP Operating Income2 $1.7B 16% $1.8B 15% 154M+ 30M+ Leading 33% Margin
Slide 5: A Compelling Investment with Strong, Sustainable Competitive Advantages
A Compelling Investment with Strong, Sustainable Competitive Advantages Large, growing and Key mega trends are driving Differentiated product portfolio underpenetrated markets patients and providers addressing global challenges and to sleep ecosystem patient preferences Robust innovation Focused 203
Slide 6: World’s market-leading health tech
Our focus areas Problems we solve Sleep Health Sleep apnea, insomnia, Sleep health issues — largely COMISA, PLMS, RLS and beyond undiagnosed — represent a global problem of staggering scope and scale. World’s Breathing Health market-leading COPD, overlap syndrome, OHVS, health tech The healthcare pa
Slide 7: Differentiated Product Portfolio Addresses Global Patient and Provider Needs
Differentiated Product Portfolio Addresses Global Patient and Provider Needs Sleep and Breathing Health Devices Masks and Other Accessories $2.7B FY25 REVENUE $1.8B FY25 REVENUE We have spent decades innovating smaller, quieter, more comfortable and more connected Mask / products that people love Da
Slide 8: Decades of Strategic Evolution Support Growth and Value Creation
Decades of Strategic Evolution Support Growth and Value Creation Resmed 2030 2015 - Today + Sleep health + Fully cloud + Breathing health 2005 - 2014 connectable + Health technology at home devices + Leading innovation in ML/AI, + Smallest, + Lower costs, Gen-AI in sleep & breathing 1989 - 2004 quie
Slide 9: Resmed Improves Quality of Life and Reduces the Impact of Chronic Disease
Resmed Improves Quality of Life and Reduces the Impact of Chronic Disease The Global State of Sleep1 Major Sleep Apnea Comorbidities and Costs AHI5 Mix of Resmed Resmed Benefits Device Users 39% lower all-cause mortality 77% with obesity2 ~40% Mild rate when treating sleep Most people apnea with CPA
Slide 10: Significant, Underpenetrated Total Addressable Market Driven by Key Megatrends
Significant, Underpenetrated Total Addressable Market Driven by Key Megatrends MARKET FOR DEVICES MARKET FOR MASKS Growing in the Growing in the mid-single digits high-single digits globally globally 480M COPD Underpenetrated OSA Market1 Overlap syndrome <20% <10% U.S. Rest of World 850M COMISA 1B+
Slide 11: Megatrends Are Driving Patients and Providers to Resmed’s Ecosystem
Megatrends Are Driving Patients and Providers to Resmed’s Ecosystem Consumers are Widespread Wearables from Consumers demand AI and digital health Pressure on more focused on adoption of GLP-1 Apple, Samsung an elevated are changing how healthcare systems their health than medications and others ex
Slide 12: 2030 Strategy Designed to Capitalize on Key Trends
2030 Strategy Designed to Capitalize on Key Trends OUR STRATEGY OUR FOCUS OUR KEY AREAS CAPABILITIES We will create products people love as well as seamless, personalized pathways for access Empower our teams Sleep Health to life-changing care Breathing Health Prioritize AI OUR OUR MISSION Health Te
Slide 13: Resmed is Creating a More Efficient, More Effective Pathway to Care
Resmed is Creating a More Efficient, More Effective Pathway to Care HEALTH JOURNEY OPT -IN MAKE THERAPY CHOICE ON THERAPY LIFETIME VALUE STAGE STAGE STAGE STAGE STAGE STAGE STAGE 0 1 2 3 4 5 6 Awareness Testing Diagnosis Prescribed PAP Start PAP therapy Compliant in 90 Days Remain after 1 Year RESME
Slide 14: Gross Margin Continues to Improve
Gross Margin Continues to Improve Non-GAAP Gross Margin1 Pipeline of Margin Improvement Drivers 61%–63% + Freight optimization + Inventory management 61.4% + Manufacturing cycle times + Scale benefits + Logistics efficiencies 59.9% + Platform standardization 59.2% 59.2% + Supply chain optimization 5
Slide 15: FY26 and 5-Year Global Outlooks Underpinned by Strong Foundation and Execution of 2030 Strategy
FY26 and 5-Year Global Outlooks Underpinned by Strong Foundation and Execution of 2030 Strategy FY26 Global Outlook 5-Year Global Outlook 61% - 63% High single digits Gross Margin, Non-GAAP % Revenue Growth 19% - 20% of revenue SG&A Earnings growth higher than revenue growth Underpinned by 2030 Stra
Slide 16: Conservative Balance Sheet Provides Flexibility
Conservative Balance Sheet Provides Flexibility As of FYE 2025 $1.2B $668M Cash Debt • Driven by strong • Includes senior notes ($250M due free cash flow July 2026, $250M due July 2029) of $1.7 B for FY25 plus term credit facility maturing June 2027 • $1.5B revolving credit facility + $75M swing lin
Slide 17: Disciplined Capital Allocation Supports Growth
Disciplined Capital Allocation Supports Growth Organic Dividends Share Acquisitions, Investment Repurchases Minority Interest $90M capital Progressive dividend Increased to Investments expenditures in FY25 policy – increased 13% $150M/quarter Tuck-in size - up to to $2.40/share for FY26 ~$500M Suppo
Slide 18: A Compelling Investment with Strong, Sustainable Competitive Advantages
A Compelling Investment with Strong, Sustainable Competitive Advantages Large, growing and Key mega trends are driving Differentiated product portfolio underpenetrated markets patients and providers addressing global challenges and to sleep ecosystem patient preferences Robust innovation Focused 203